

## Translational Cancer Research is indexed in Scopus

Nancy Q. Zhong

Editorial Office, AME Publishing Company, Guangzhou 510220, China

Correspondence to: Nancy Q. Zhong, Editorial Office, AME Publishing Company, Guangzhou 510220, China. Email: tcr@amepc.org.

Submitted Aug 10, 2015. Accepted for publication Aug 10, 2015.

doi: 10.3978/j.issn.2218-676X.2015.08.13

View this article at: <http://dx.doi.org/10.3978/j.issn.2218-676X.2015.08.13>

With pleasure, we are here to announce that *Translational Cancer Research (TCR)* has been accepted for inclusion in Scopus. Within months, article titles, abstracts, and references of *TCR* articles will be searchable in Scopus. It is hopeful that more researchers and clinicians could access *TCR* articles via the Scopus database with the inclusion.

Scopus is the largest abstract and citation database of peer-reviewed literature, featuring smart tools to track, analyze and visualize research (1). It is appreciated that the Scopus evaluation team comment on the journal as “a well presented journal with high quality content”.

*Translational Cancer Research (Transl Cancer Res, TCR)*; Print ISSN: 2218-676X; Online ISSN 2219-6803; [www.thetcr.org](http://www.thetcr.org)), is an open access, peer-reviewed journal launched in June 2012. It publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients, aiming to promote a rapid exchange of scientific information between clinicians and scientists worldwide.

The operation of *TCR* is driven by the leadership and passion of Editor-in-Chief, Prof. Eric Chuang; co-Editor-in-Chief, Dr. Huan Giap; and Associate Editor-in-Chief, Dr. Binghe Xu. They devote their time and bring their decades of experience in scientific research and publications in managing this journal. *TCR* has now been published 19 issues including 13 focused issues respectively on topics as followed:

- “Particle Beam Therapy I & II” (Huan Giap, Scripps Proton Therapy Center);
- “DNA Damage and Repair” (Benjamin P. C. Chen & David J. Chen, U. Texas Southwestern Medical Center at Dallas);

- “Nanotechnology in Radiation Research” (Rao V. L. Papineni, University of Kansas Medical Center; Pataje G. Prasanna & Mansoor M. Ahmed, National Cancer Institute, National Institutes of Health);
- “Stem Cell in Cancer” (Daohong Zhou, University of Arkansas for Medical Sciences; Chuan-Yuan Li, Duke University Medical Center);
- “Liver Cancer” (Catherine T. Frenette, Scripps Center for Organ and Cell Transplantation);
- “IORT I & II” (Frederik Wenz & Elena Sperk & Frederik Wenz, University of Heidelberg; Pedro Lara, University of Las Palmas);
- “Statistical and Bioinformatics Applications in Biomedical Omics Research” (Dung-Tsa Chen & Yian Ann Chen, Moffitt Cancer Center);
- “SBRT/SRS in Radiation Research” (Sandra Vermuelen, Swedish Medical Center; Kevin T. Murphy, University of California; Huan Giap, Scripps Proton Therapy Center);
- “High Intensity Focused Ultrasound” (Giusi Irma Forte & Giorgio Russo, Istituto di Bioimmagini e Fisiologia Molecolare);
- “Epithelial Ovarian Cancer Treatment: Integrating Molecular Targeting” (Franco Muggia & Eleonora Teplinsky, New York University Langone Medical Center);
- “Application of Genomic Technologies in Cancer Research” (Jian-Bing Fan, PhD, Southern Medical University).

More focused issues on topics respectively of recent advances in radiotherapy and targeted therapies for lung cancer, “Lysophospholipids on Immunity and Cancer” “Pancreatic Cancer”, “Combinatorial Cancer Therapy-Bench to Personalized Medicine”, “Radiation Induced Cancer”, and “Circulating Tumor Cells” etc., are now

proceeding with efforts of the editors.

In addition to the coming indexing of titles, abstracts and references in Scopus, *TCR* owns the OJS system that deal with manuscripts from submission, reviewing to decision making to ensure short term of turnaround vary from one week to 2 months. No article process fee or publication fee is required to publish in *TCR*. We highly encourage you to submit your manuscripts to *TCR*.

*TCR* Editorial Team:

Eric Y. Chuang, Sc.D, Editor-in-Chief;  
Huan Giap, MD, PhD, MD, co-Editor-in- Chief;  
Binghe Xu, Prof., MD, PhD, Associate Editor-in-  
Chief;  
Nancy Q. Zhong, Corresponding Editor;  
Molly J. Wang, Science Editor;  
Lucille L. Ye, Science Editor.

### Acknowledgments

*Funding:* None.

### Footnote

*Provenance and Peer Review:* This article was commissioned by the editorial office, *Translational Cancer Research*. The article did not undergo external peer review.

**Cite this article as:** Zhong NQ. *Translational Cancer Research* is indexed in Scopus. *Transl Cancer Res* 2015;4(4):449-450. doi: 10.3978/j.issn.2218-676X.2015.08.13

*Conflicts of Interest:* The author has completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.3978/j.issn.2218-676X.2015.08.13>). Nancy Q. Zhong reports that she is a full-time employee of the publisher of the journal, AME Publishing Company.

*Ethical Statement:* The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

### References

1. Scopus. Available online: <http://www.elsevier.com/solutions/scopus>